The Fasting Mimicking Diet: ProLon, IGF-1, and Autophagy Evidence

Five Days, Three Times a Year

The Fasting Mimicking Diet (FMD) is not a fasting protocol in the strict sense — it is a precisely engineered low-calorie, low-protein, low-carbohydrate, high-fat dietary pattern that tricks the body into activating fasting-like cellular programs while still providing food. Developed by Valter Longo at the USC Longevity Institute, the commercial implementation called ProLon delivers approximately 1,090 kcal on day 1 and 725 kcal on days 2–5, with a specific macronutrient ratio designed to suppress insulin and IGF-1 signaling while sparing muscle via adequate (but not excessive) protein. The hypothesis: periodic cellular "stress" activates protective mechanisms that continuous caloric restriction cannot, because the recovery phase between cycles may be as important as the restriction phase itself.

IGF-1: The Growth Signal That Accelerates Aging

Insulin-like growth factor 1 (IGF-1) is produced primarily by the liver in response to growth hormone and dietary protein. It drives anabolic growth — essential in childhood and adolescence, but in adulthood, chronically elevated IGF-1 is associated with increased cancer risk and accelerated cellular aging. Longo's research in long-lived populations, including Laron syndrome patients (who have congenital IGF-1 receptor deficiency), has consistently linked low IGF-1 to longevity and reduced cancer incidence. A 2015 pilot clinical trial of the FMD in 19 subjects (Brandhorst et al., Cell Metabolism) found three monthly cycles reduced IGF-1 by approximately 15%, reduced fasting glucose, lowered blood pressure, and reduced trunk fat while preserving lean mass. These changes reversed substantially in the re-feeding period — but each new FMD cycle renewed them.

Autophagy: Cellular Housekeeping at Its Peak

Autophagy (from Greek: "self-eating") is the cellular process by which damaged organelles, misfolded proteins, and dysfunctional components are engulfed by autophagosomes and degraded by lysosomes for recycling. Its induction requires suppression of mTOR (mechanistic target of rapamycin), the master growth-signaling kinase that is activated by amino acids and glucose. Fasting suppresses both — making true fasting and FMD the most reliable autophagy inducers known. The 2016 Nobel Prize in Physiology or Medicine was awarded to Yoshinori Ohsumi for discovering autophagy's molecular mechanisms. Human measurement of autophagy remains technically challenging; most published evidence comes from cell culture and animal studies. That said, elevated autophagic flux markers have been detected in peripheral blood monocytes of fasting human subjects.

FMD vs. Continuous Caloric Restriction

The key mechanistic distinction between FMD and continuous caloric restriction (CR) is the re-feeding phase. Longo's animal work showed that cycles of FMD followed by re-feeding regenerated immune system cells, including through stem cell activation — an effect not seen with continuous CR at equivalent caloric deficit. In mouse models, FMD cycles extended lifespan by approximately 11%, reduced cancer incidence by 45%, and improved cognitive performance in old mice. Whether these findings translate to humans at the same magnitude remains unknown. The human trial data is compelling but limited to short-duration, small-sample studies.

• The ProLon program provides pre-packaged food (soups, bars, supplements, teas) designed to achieve the precise macronutrient ratios. The cost is approximately $250–$300 per 5-day kit.
• Do-it-yourself FMD approximations using vegetable soups, olive oil, nuts, and herbal tea can approximate the macronutrient targets, though adherence to the exact ratio is harder without pre-packaging.
• Longo recommends the FMD 3–4 times per year for healthy individuals and monthly for those with metabolic risk factors — always under physician guidance for the latter.

TRIPMASTER: FMD in Multiple Sclerosis

The TRIPMASTER trial (NCT03539965) investigated whether the FMD could reduce disease activity in relapsing-remitting multiple sclerosis (RRMS). The rationale drew from mouse studies showing that FMD cycles reduced MS-like neurological disease by regenerating myelin-producing oligodendrocytes and resetting pro-inflammatory T-cell populations. The published results (Bahr et al., Cell Reports Medicine 2023) found that patients randomized to either the FMD or a ketogenic diet for 18 months showed significantly reduced fatigue and improved quality of life scores compared to a regular Mediterranean diet control. Crucially, MRI lesion counts and relapse rates showed non-significant trends favoring the dietary interventions — underpowered for definitive conclusions but mechanistically suggestive. Multiple sclerosis researchers consider the TRIPMASTER findings hypothesis-generating, warranting a larger adequately powered RCT.

Periodic vs. Continuous Caloric Restriction: A Distinct Biology

The FMD challenge to conventional caloric restriction thinking is this: the biological response to a severe 5-day periodic restriction followed by re-feeding appears to differ from the response to an equivalent weekly caloric deficit spread evenly across all days. The periodic pattern activates AMPK and suppresses mTOR more dramatically; the re-feeding activates IGF-1 and mTOR transiently, potentially stimulating stem cell proliferation and tissue renewal. Whether this proposed "hormetic stress" model produces clinically meaningful human health benefits beyond those achievable through continuous moderate restriction remains the central unanswered question in FMD research.

This article is for informational purposes only. Consult a qualified healthcare professional.